Cellectar Biosciences, a Madison company working on cancer-fighting medications, is cheering early patient test results of its main compound, but it has ended production of the drug here, cutting jobs, and last week the company learned its supply of the drug has been temporarily halted by federal regulators.

CLR 131, Cellectar’s lead drug candidate, is being tested on patients with recurrences of a variety of blood cancers, including multiple myeloma and several types of lymphoma, in a phase 2 trial.

Initial results in patients with diffuse large B-cell lymphoma, show that after a single dose of CLR 131, 33 percent of the patients saw their tumors reduced, in amounts ranging from 60 percent to more than 90 percent. The company did not say how many people were in that group. Half of the participants had some tumor shrinkage or their conditions were stabilized after receiving the medication.

“We are very encouraged by the strong response rates and meaningful reductions in tumor volumes,” Cellectar CEO James Caruso said. Read the full story here.

Read the full story here.